MK-4409

MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.[1][2]

MK-4409
Clinical data
ATC code
  • None
Legal status
Legal status
Identifiers
IUPAC name
  • 2-[5-[5-(5-Chloropyridin-2-yl)sulfanyl-2-(4-fluorophenyl)-1,3-oxazol-4-yl]pyridin-2-yl]propan-2-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H17FN3O2S
Molar mass406.46 g·mol−1
3D model (JSmol)
SMILES
  • c3nc(C(O)(C)C)ccc3-c1nc(-c4ccc(F)cc4)oc1Sc(nc2)ccc2Cl
InChI
  • InChI=1S/C22H17ClFN3O2S/c1-22(2,28)17-9-5-14(11-25-17)19-21(30-18-10-6-15(23)12-26-18)29-20(27-19)13-3-7-16(24)8-4-13/h3-12,28H,1-2H3
  • Key:DBZMCSVIITXLCC-UHFFFAOYSA-N

See also

References
  1. Chobanian HR, Guo Y, Liu P, Chioda MD, Fung S, Lanza TJ, et al. (June 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–21. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
  2. Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.
  • "MK 4409". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.